AR008680A1 - Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion - Google Patents

Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion

Info

Publication number
AR008680A1
AR008680A1 ARP970104847A ARP970104847A AR008680A1 AR 008680 A1 AR008680 A1 AR 008680A1 AR P970104847 A ARP970104847 A AR P970104847A AR P970104847 A ARP970104847 A AR P970104847A AR 008680 A1 AR008680 A1 AR 008680A1
Authority
AR
Argentina
Prior art keywords
substitutes
platelets
preparation
fibrinogen
methods suitable
Prior art date
Application number
ARP970104847A
Other languages
English (en)
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26310263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR008680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9621886.2A external-priority patent/GB9621886D0/en
Priority claimed from GBGB9702652.0A external-priority patent/GB9702652D0/en
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of AR008680A1 publication Critical patent/AR008680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Los sustitutos de plaquetas, que comprenden fibrinogeno, o productos análogos que son utiles en terapia, comprenden en portador insoluble al cualestá adherido una proteína activa esencialmente no degradada que incluye la secuencia RGD. Dichos conjugados pueden prepararse mediante un procedimiento deconjugacion que comprende 0,01 a 2,5% en peso de fibrinogeno activo y no más de 50% de fibrinogeno inactivo.
ARP970104847A 1996-10-21 1997-10-20 Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion AR008680A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621886.2A GB9621886D0 (en) 1996-10-21 1996-10-21 Microparticles and their therapeutic use
GBGB9702652.0A GB9702652D0 (en) 1997-02-10 1997-02-10 Conjugates and their preparation

Publications (1)

Publication Number Publication Date
AR008680A1 true AR008680A1 (es) 2000-02-09

Family

ID=26310263

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104847A AR008680A1 (es) 1996-10-21 1997-10-20 Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion

Country Status (10)

Country Link
US (1) US5977313A (es)
EP (1) EP1028752B1 (es)
JP (1) JP2001504813A (es)
AR (1) AR008680A1 (es)
AT (1) ATE284714T1 (es)
AU (1) AU718956B2 (es)
CA (1) CA2269335C (es)
DE (1) DE69731985T2 (es)
ES (1) ES2232862T3 (es)
WO (1) WO1998017319A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
AU741528B2 (en) 1997-06-05 2001-12-06 Hemosphere, Inc. Fibrinogen-coated microspheres
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US20030021777A1 (en) * 1998-02-20 2003-01-30 Roy Harris Product comprising bound fibrinogen and thrombin for use in wound therapy or surgical repair
GB9825105D0 (en) * 1998-11-16 1999-01-13 Andaris Ltd Pharamaceutical conjugates
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) * 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
WO2003028640A2 (en) * 2001-10-03 2003-04-10 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
US9119897B2 (en) 2009-05-28 2015-09-01 Profibrix B.V. Dry powder fibrin sealant
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
GB201201751D0 (en) 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
US8999376B2 (en) 2012-02-03 2015-04-07 Xcede Technologies, Inc. Tissue patch
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
US9540548B1 (en) 2015-08-07 2017-01-10 Xcede Technologies, Inc. Adhesive compositions and related methods
US10588998B2 (en) 2015-08-07 2020-03-17 Xcede Technologies, Inc. Adhesive compositions and related methods
US9833538B2 (en) 2015-08-07 2017-12-05 Xcede Technologies, Inc. Adhesive compositions and related methods
CN107686508B (zh) * 2016-08-05 2021-02-12 首都医科大学 阿霉素-rgds,其合成,活性和应用
CN107686507B (zh) * 2016-08-05 2021-02-12 首都医科大学 Rgds-阿霉素,其合成,活性和应用
EP3634459A4 (en) 2017-02-10 2021-01-06 Washington University ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
AU3149289A (en) * 1988-03-18 1989-09-21 Rockefeller University, The Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
DE69118861T2 (de) * 1991-01-10 1996-09-05 Basf Corp Verfahren zur Vernetzen von Gelatine und Aufnahme eines Materials
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DE69124357T2 (de) * 1991-01-15 1997-07-10 Hemosphere Inc Protein Nanomatrizen und Verfahren zur Herstellung
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
WO1992013495A1 (en) * 1991-02-07 1992-08-20 Fibratek, Inc. Fibrinogen based adhesive
WO1992013547A1 (en) * 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
ES2191721T3 (es) * 1994-12-16 2003-09-16 Elan Drug Delivery Ltd Microparticulas reticuladas y su utilizacion como vehiculos terapeuticos.
EP0727225A3 (en) * 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
AU6100296A (en) * 1995-06-06 1996-12-24 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use

Also Published As

Publication number Publication date
ES2232862T3 (es) 2005-06-01
JP2001504813A (ja) 2001-04-10
EP1028752A2 (en) 2000-08-23
DE69731985T2 (de) 2005-12-29
EP1028752B1 (en) 2004-12-15
CA2269335C (en) 2010-05-25
AU4713597A (en) 1998-05-15
ATE284714T1 (de) 2005-01-15
WO1998017319A2 (en) 1998-04-30
CA2269335A1 (en) 1998-04-30
US5977313A (en) 1999-11-02
AU718956B2 (en) 2000-05-04
WO1998017319A3 (en) 1998-06-11
DE69731985D1 (de) 2005-01-20

Similar Documents

Publication Publication Date Title
AR008680A1 (es) Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion
ES2058139T3 (es) Compuestos complejos de bioflavonoides con fosfolipidos, su preparacion y uso, y composiciones farmaceuticas y cosmeticas que los contienen.
ES2058151T3 (es) Complejos de saponinas con fosfolipidos y composiciones farmaceuticas y cosmeticas que los contienen.
PT977564E (pt) Forscolina para promocao da massa corporal magra
ATE65402T1 (de) Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
ES2047014T3 (es) Procedimiento para preparar un catalizador basado en plata y procedimiento para epoxidar olefinas superiores.
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
IT8847871A0 (it) Ne e loro impiego come medicamenti derivati peptidici,loro preparazio-
ES2095846T3 (es) Composicion estable y liofilizada de un ester/eter de polihematoporfirina.
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
ES2041617T3 (es) Productos intermedios para agentes de quelacion con simetria prefijada y procedimiento para su preparacion.
IT9022439A0 (it) Derivati del glicerolo un procedimento per la loro preparazione e composizioni terapeutiche che li contengono
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES473087A1 (es) Procedimiento para la preparacion de eritrocitos intactos modificados.
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2085852T3 (es) Derivados de piperazina ansioliticamente activos.
PT90298A (pt) Processo para a preparacao de derivados de pro-uroquinase de baixo peso molecular e de composicoes farmaceuticas que os contem
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.
ATE26109T1 (de) Acetylcystein-salze, ihre herstellung und verwendung.
ES2091940T3 (es) Composicion basada en oligomero de hemoglobina y procedimiento para elaborar la misma.
IT1235760B (it) Derivati del catecolo, procedimento per la loro preparazione e composizioni terapeutiche che li contengono
ES2178760T3 (es) Uso de 2-mercaptoetanosulfanato de sodio en cirugia.